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Twenty-two consecutive liver allograft recipients, 
who tested positive for immunoglobulin G (lgG) lympho-
cytotoxicity were subjected to pretransplantion and 
posttransplantation immunologic monitoring of anti-
donor IgG Iymphocytotoxic antibody titers. total hemo-
lytic complement activity (CH.oo), circulating immune 
complexes (CIC), and platelet counts in an effort to im-
prove our understanding of the preformed antibody 
state in clinical hepatic transplantation. Ten contempo-
raneous liver transplant recipients whose crossmatch 
results were negative and who experienced severe hepa-
tocellular damage early after transplantation were in-
cluded as controls. Crossmatch test results were nega-
tive 1 day after transplantation and during the 1 month 
follow-up remained negative in 14 of 22 (64%) sensitized 
recipients, most of whom had relatively low (:s 1:16) anti-
donor IgG antibody titers before transplantation. After 
transplantation, this group and the control group expe-
rienced no thrombocytopenia. no increase of CIC, and a 
gradual increase in CH.oo activity that reached normal 
levels within 1 week. A strong negative correlation be-
tween prothrombin time (PT) and CHuII) activity in these 
groups of patients suggested that changes in CH.oo activ-
ity (P < .0005) were tightly linked to liver synthetic func-
tion. In contrast. the crossmatch test results remained 
positive after transplantation in 8 of 22 (36%) sensitized 
recipients. all of whom had relatively high (>1:32 to 
1024) pre transplantation titers of anti-donor IgG anti-
bodies. After transplantation these patients developed 
a syndrome that was characterized by decreased CH.oo 
activity and increased CIC compared with pretrans-
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plantation levels and refractory thrombocytopenia that 
was associated with a 5()l7c allograft failure rate because 
of biopsy-proven humoral and acute (cellular) rejection. 
Moreover, the lack of a strong negative correlation be-
tween PT and CHIIlII activity (P = .1) in this group of 
patients suggested that the hypocomplementemia was 
not tightly linked to liver synthetic function. Before 
transplantation. determination of anti-donor antibody 
class (lgG) and titer alone showed a strong negative pre-
dictive value (100%) but less than optimal positive pre-
dictive value (67%) for identifying patients who experi-
enced the posttransplantation syndrome described 
above. Therefore, evaluation of platelet counts, CHlllfI ac-
tivity, CIC, persistence of anti-donor antibodies and re-
sults of a liver biopsy performed after transplantation 
assisted in identifying sensitized liver allograft recipi-
ents who suffered the adverse consequences of the pre-
formed antibody state. (HEPATOLOGY 1995;21:1345-1352.) 
Although the resistance of liver allografts to humoral 
rejection is well known. we have recently reported a 
characteristic clinical 1.2 and pathologicafl syndrome in 
sensitized primary liver allograft recipients. As a 
group, patients whose crossmatch results were testing 
positive for immunoglobulin G (IgG) lymphocytotox-
icity are more likely to experience rejection and allo-
graft failure. 1':1 yet it is difficult to predict these events 
before transplantation. Moreover. tangible evidence of 
type IIIIII hypersensitivity reactions have been difficult 
to obtain in either presensitized humans l .7 or experi-
mental animals.!!-IO 
The mechanisms used to explain hepatic resistance 
to preformed antibody states have also been offered as 
reasoning for the difficulties in finding traces of hu-
moral-related injury. Traditional explanations for this 
resistance are (1) release of soluble class I major histo-
compatibility complex antigens by the liver; (2) forma-
tion of immune complexes; (3) Kupffer cell phagocytosis 
of activated platelets and immune complexes: (4) the 
structurally and antigenically unique sinusoidal vascu-
lature: and (5) the dual afferent hepatic blood supply. I I 
More recently. the realization that complement-medi-
ated lysis of a target cell is less efficient if the com-
plement and the target cell have a common source 
is yet another possible explanation for the hepatic 
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resistanceKD~ However. regardless of the defense 
mechanisms. experiments with animal ':u, and clinical 
data 1-3.15-10 now conclusivelv show that in some cases 
IgG lyrnphocytotoxic antib~dies can override hepatic 
defenses and have a deleterious effect in liver trans-
plantation. even if they do not precipitate "hyperacute" 
rejection. 
The goal of this study was to determine if the func-
tional consequences of presensitized states in clinical 
liver transplantation could be more precisely charac-
terized by defining the level of sensitization before 
transplantation and looking for a syndrome marked by 
consumption of factors important in humoral rejection 
after transplantation. Therefore. we prospectively as-
sayed donor-specific antibody subclass and titers, se-
rum complement activity, platelet counts. and circulat-
ing immune complexes (CIC) in sensitized recipients 
before and after clinical liver transplantation. Because 
humoral rejection is dependent on complement activa-
tion,19.20 and the liver is also the principal site of com-
plement biosynthesis.2 1.22 the patients with positive 
crossmatch results were compared with a group of con-
trols who had negative crossmatch results and experi-
enced severe hepatocellular injury related to "preserva-
tion" injury. 
PATIENTS AND METHODS 
Patient Selection. Between March 1. 1991. and December 
31. 1991, 22 of 277 (8%) adult patients (> 16 years of age! 
received a primary orthotopic liver allograft at the Pittsburgh 
Transplant Institute. University of Pittsburgh. from a donor 
whose crossmatch test results were positive. Selection of the 
contemporaneous control patients whose crossmatch test re-
sults were negative was based on the presence of severe "pres-
ervation" injury (aspartate transaminase lAST! > 2.500 UI 
mL on day 1 of posttransplantationK~g All donor livers were 
preserved with the University of Wisconsin solution. 
Both groups were prospectively studied during the first 
month after transplantation for the presence of IgG anti-
donor lymphocytotoxic antibodies. the observation of total 
hemolytic complement activity (CH"H')' and the detection of 
circulating immune complexes. Blood samples for testing 
were drawn pretransplantation and i-day posttransplanta-
tion on all patients. Thereafter. weekly samples (with a 2-
day window) were obtained for 1 month. unless the patient 
di~dK experienced graft failure. or was discharged from the 
hospital. The results of the above tests were then correlated 
with patient and graft survival and the postoperative course. 
Immuno.uppre .. ion. The standard protocol consisted of 
FK506 (Fujisawa Pharmaceuticals. Japan! given via continu-
ous mtravenous infusion of 0.1 mgikg/d and then converted 
to an oral dose of 0.15 mgikg every 12 hours with the return 
of bowel functIOn. Subsequent dosage adjustments were 
guided by the quality of graft function. rejection. toxiCity. 
and FK506 plasma trough levels Eusuall~D <:2 ng/mLI. All 
hut three of the patients with pOSitive crossmatch results 
received an mtravenous operative dose of I g of methylpred-
nisolone. followed bv a 5-day taper from 200 mg to 20 mg 
("recycling"). Humoral and acute rejection episodes were hiS-
tologIcally confirmedJ · 11 and treated with either a l-g bolus 
of methylprednisolone or a "recycling" of high-dose steroids. 
If rejection persIsted. a 3- to 5-day course of 5 to 10 mg/d of 
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OKT3 (Ortho PharmaceutIcals. Raritan. NJ, was adminis-
tered. 
qreat~nt With Pro.taRlandin E, Fourteen patients with 
positive crossmatch results and all the control patients with 
negative crossmatch results and hepatocellular damage re-
ceIved treatment with prostaglandin EI (PGE 1 ) (Prostln YR. 
UpJohn. Kalamazoo. MI) 0,2 to 0.6 pgikg/h intravenously for 
5 to 7 davs after transplantation. 
Crou~atch Tellt. PretransplantatlOn sera was drawn im-
mediatelv before transplantation and tested for cytotoxic ac-
tivltv before and after treatment with dithiothreitol. which 
inactivates IgM antibodiesK~l Donor T lymphocytes isolateu 
from spleen or lymph nodes using CD3-conjugated dynabead:-
(Dvnal. Inc .. (ireat Neck. NY, were used as targets, 
The cvtotoxicitv test was done according to Nationallnsti-
tutes of Health ~tandards with one wash: 1 pL of 2 x lOtil 
mL T lymphocytes was placed into 1 pL of serum. followed 
by a I-hour incubation at room temperature. The titer of 
antibodies present was determined by a 1:2 serial dilution of 
the sera with RPMI 1640, After one wash. addition of 5 pL 
of rabbit complement for 1 hour at room temperature pro-
duced Ivsis that was evaluated using trypan blue exclusion. 
Crossm-atch test results were considered positive ifmore than 
507£ donor lymphocytes were killed after treatment of the 
serum with dithiothreitol. 
Total Comple~nt Activity Test. Measurement of total 
complement activity was based on the ability of complement 
to lyse sensitized red blood cells (Kallestad. Inc .. Austin. TX 
The test serum radially diffused from wells in an agarose gl'1 
that contained standardized sheep erythrocytes that were 
sensitized with hemolysin. The extent of lysis caused by the 
test serum sample compared with that caused by reference 
sera run simultaneously provided an estimate of total com-
plement activity (CH uK,). The results were reported in units! 
mL (normal value> 60 p/mLl. 
Detection of Circulating Immune Complexe •. CIC were 
qualitatively detected using zone electrophoresis on agarose 
gels as reported by Kelly et alK~R In principle. an antibody-
antigen immune complex has a net surface charge different 
from the isolated constituents. This property, together with 
the clonal restriction of the antibody response. causes distinc-
tive patterns that are apparent in stained agarose gels after 
routine zone electrophoresis. 
Statistical Analnis. The Wilcoxon test for two indepen-
dent samples was ~sed to compare the characteristics of both 
crossmatch groups before transplantatIOn and the CH lOo ac-
tivity before and after transplantation. The Fisher's exact 
test was used to compare the incidence of CIC before and 
after transplantation. One-way ANOVA was used to compare 
AST. total bilirubin. and prothrombin time (PT) during the 
first 4 weeks after transplantation. The possibility of a rela-
tionship, if any. between CHIOU and PT was determined by 
linear regressIOn analysis. 
RESULTS 
Patient Immunolopic Profiles Before Transplantation 
Table 1 shows the pretransplantation profile of the 
22 patients with positive crossmatch results and the 10 
controls with negative crossmatch results. As expected. 
panel-reactive antibodies in sera pretreated with 01-
thiothreitol were higher in the patients with positive 
crossmatch results: 80.0 ::: 29.30i- versus 3,5 == 4.71} (p 
.: ,DOll. Consistent with the method of patient selec-
tion. mean serum AST 1 day after transplantation was 
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TABLE 1. IgG Lymphocytotoxic Cro88match Positive Cases 
and Crossmatch Nellative Controls With 
Hepatocellular Damage 
Po.itivp Negative 
Cro ... match Cros.match 
iUotluits Re8ults P 
No. of patIents 22 10 NS 
Age 47 :: l:l 54 :: 14 NS 
:'.Iale/female 7/15 6/4 NS 
Cold ischemIc tIme Ihrl 12.0 ~ 4.0 13.3 :: 3.9 NS 
PRAS' 80 :: 29 4:: 2 <.001 
AST on day l' 1.434 : 1.040 6.094 :: 3.700 <.001 
Orij:Pnal dIsease 
Hepatocellular 15 i NS 
Cholestatic i 3 NS 
AbbrevIations: NS. not signIficant; PRA, panel reactIve antibodies. 
* Mean:: SD. 
1,434 ~ 1,040 U/mL in the group with positive cross-
match results and 6,094 ~ 3,700 U/mL in the controls 
(p < .0011. Pretransplantation anti-donor IgG lympho-
cytotoxic Ab titers available in 20 of 22 patients whose 
crossmatch results were positive showed levels greater 
than 1:32 in 12 patients (60lk), 1:16 in 1 patient (5%), 
greater than 1:8 in 2 patients (10%), 1:2 in 3 patients 
( 15%), and 1: 1 in 2 patients (10%). There were no statis-
tically significant differences between the two groups 
in total CH IOO activity. circulating immune complexes, 
age, sex, cold ischemic time, or nature of the original 
disease. More females had positive crossmatch results. 
as expected. 
Posttransplantation Crossmatch Testing and 
Correlation With Pretransplantation Antibody Titers 
Analysis of the posttransplantation crossmatch test 
results separated the sensitized recipients into two 
groups. Repeat crossmatch testing results were nega-
tive 1 day after transplantation and remained negative 
in 14 of22 (649'(') patients whose crossmatch result was 
positive before engraftment. In the remaining 8 (36%) 
patients with positive crossmatch results. donor-spe-
cific IgG lymphocytotoxic antibodies persisted for 4 
weeks in 5 patients and for 3 weeks in 2 patients after 
transplantation. One patient required retransplanta-
tion on day 2. 
The pretransplantation antibody titer was greater 
than 1:32 in all 8 patients with persistently positive 
crossmatch results after transplantation. However. the 
crossmatch test results were negative 1 day after trans-
plantation and remained negative in 4 other patients 
with pretransplantation titers greater than 1:32 and 
in all of the patients with pretransplantation titers of 
less than 1: 16. A pretransplantation titer less than or 
equal to 1: 16 had a 100% negative-predictive value and 
G79'c positive-predictive value for persistently positive 
cross match results after transplantation. The pre-
transplantation PRA did not show a statistically sig-
nificant difference between patients with persistently 
positive crossmatch results and patients whose cross-
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match results became negative: 75.1lk ::: 34.1 C;'c (range 
10C;'c to 100C;'cl versus 77.39'c ~ 23.0?(' (range 40('k to 
100lk l. respectively. Five of 8 patients (63lk) with per-
sistent positive crossmatch results and 9 of 14 patients 
(64Cfr) whose crossmatch results became negative after 
transplantation underwent treatment with PGE 1 • 
Total Complement Activity and Relationship to Liver 
Synthetic Function and Liver Injury Tests After 
Transplantation 
Mter transplantation, patients with persistently pos-
itive crossmatch results showed a significant decrease 
in CH100 activity during the first 2 weeks after trans-
plantation in comparison with pretransplantation lev-
els (Fig. 1). These patients also showed significantly 
less CH IOO activity during the first 4 weeks in compari-
son to patients whose crossmatch results were negative 
before transplantation and patients whose crossmatch 
results became negative after transplantation (Fig. 1). 
No differences were found at any time between the 
latter two groups. although there was a trend toward 
less complement activity in patients whose crossmatch 
results changed from positive to negative. 
The relationship of CH lOo activity to liver synthetic 
function was quantitatively assessed by a linear regres-
sion analysis between CH IOO levels and PT. CH lOO 
showed a significant negative correlation with the PT 
in patients with negative crossmatch results (r - .56; 
P < .0005) (Fig. 2A) and in patients whose crossmatch 
results became negative after transplantation (r - .52; 
P < .0005) (Fig. 2B>. In contrast, a definite negative 
correlation was not found in patients with persistently 
positive crossmatch results (r - .3; P = .1) (Fig. 2C). 
Table 2 shows the mean AST, total bilirubin, and PT 
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FIG. 2. Relationship between CH ,oo and PT in liver transplant 
recIpients with negative crossmatch results and severe hepatocellu-
lar damage (A). liver transplant recipients with positive IgG lympho-
cytotoxic crossmatch results pretransplantation that became nega-
tive posttransplantatlOn (B). and liver transplant recipients with 
positive IgG lymphocytotoxic crossmatch results pretransplantatlon 
and posttransplantation (C)' 
during the first 4 weeks after transplantation. Controls 
whose crossmatch results were negative and with pres-
ervation injury and negative crossmatch results experi-
enced higher AST and total bilirubin values as well as 
lower PT compared with both groups of patients with 
positive crossmatch results. 
Immune Complex Detection 
Although no difference between the three groups of 
patients in the incidence of CICs was detected before 
transplantation (22% to 33%), after transplantation all 
(100%) of the patients with persistently positive cross-
match results developed CIC (P < .02 compared with 
pretransplant) that persisted for 3 weeks. In contrast. 
CICs were detected on weeks 1. 2. and 3 in only 50%. 
33t')C. and 30% of the patients whose crossmatch results 
became negative and in 20%. 20%. and 337c of the con-
trols with negative crossmatch results (p < .05 com-
pared with patients with persistently positive cross-
match results). 
Blood Product Usage and Platelet Counts 
There were no statistically significant differences 
:J.mong the three groups in the intraoperative or postop-
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erative blood product requirements. except that the pa-
tients with positive crossmatch results needed more 
platelets (data not shown) during transplantation and 
for the first 4 weeks (data not shown) after transplanta-
tion (P < .001). Despite increased platelet transfusions, 
the mean platelet counts in patients with persistently 
positive crossmatch results were still significantly less 
(data not shown) during the first 4 weeks after trans-
plantation than patients with negative crossmatch re-
sults and those whose crossmatch results became nega-
tive after transplantation (P< .001l. 
Clinicopathological Course After Transplantation 
As shown in Table 3. at least seven ofthe eight (88%) 
patients with persistently positive crossmatch results 
had biopsy results that confirmed rejection, which re-
sulted in allograft failure requiring retransplantation 
in four patients (50%). Six of these eight patients had 
biopsy changes that resembled preservation injury 
and/or large duct stricturing that previously had been 
attributed to humoral rejection.3 No biopsy specimens 
from the early posttransplantation course were avail-
able in the remaining patient. although the failed allo-
graft removed on day 31 showed evidence of both hu-
moral and acute rejection. There was one graft failure 
from pure humoral rejection on day 3, and three others 
failed from severe acute and humoral rejection on days 
10. 35, and 39. The patient whose allograft failed be-
cause of pure humoral rejection had a pretransplanta-
tion crossmatch titer 1:1,024. The other three patients 
who experienced allograft failure did not receive post-
transplantation steroid "recycling" or treatment with 
PGE 1 because of early infectious complications. 
Ten of the thirteen (77%) patients whose crossmatch 
results became negative after transplantation and who 
were subjected to biopsy in less than 30 days had acute 
TABLE 2. AST, Total Bilirubin. and PI' During the 
Fint Month Mter Transplantation 
Week 1 Week 2 Week 3 Week 4 
AST lUlL I 
A 1.059 ~ 956' 73 ~ 61 49 ~ 27 56 :!: 41' 
B 373 :!: 298 48 :!: 40 35 :!: 17 38 :!: 21 
C 2.134 c 1.825t 114 :!: 103t 70 ~ 69t 58 :!: 42" 
Total bilirubin 
I ml(ldL I 
A i.7 ~ 6.9 9.3 :!: 8.A· 6.7 :: 5.5' 4.4 ~ 3.5 
B 6.2 ~ 3.7 4.4 :!: 3.8 3.6 ~ 3.3 3.3 ~ 2.5 
C 12.2 :: 8.17 10.5 :: 8.5' 7.6 :: 6.7' 6.3 ~ 5.8' 
PT (SI 
A 14.6 :: 2.5 12.9 :!: 0.6' 1~KT :- 0.8 12.6 ~ 0.6 
II 13.8 :!: 1.6 12.5 :- 0.7 12.7 :: 0.6 12.7 c 0.7 
(' 16.6 :: :1.7t 13.1 :- 1.1' 12.8 :!: 0.8 12.9:!: 0.9 
NOTE. Data represent Mean::: SD. Patients are grouped as fol· 
lows: A. patients WIth pOSItive IgG lymphocytotoxic crossmatch reo 
suits pretransplantatlOn and posttransplantatlOn: B. patients with 
pretransplantatlOn positive crossmatch resuli~ that became negative 
posttransplantatlon; C. controls WIth negative crossmatch results. 
, l' K~ .U5 with !n'0UP B. 
7 P < .U5 with !n'oup A and B. 
.. ---"D-K--~"K-
-----K---------~K~------
HEPATOLOGY Vol. 21. No.5, 1995 MANEZ ET AL 1349 
TABLE 3. Pretransplantation and Posttransplantation Crossmatch Results and Clinicopathological Follow-up of Patients 
With Positive Crosllmatch Results 
Pretran.plant Poattransplant Hiatololfical 
Cro •• match (;roNmatch Evidence of 
Patient (titer} (titerl PGE, Rejection (d} Graft Survival Id} Clinicopathololrical Follow-up Id} 
Pos (> 1:321 mo~ I> 1:321 Yes Yes (16) Died (3501 Duct stnctures (116). metastatic hepatoma 1350} 
2 Pos 1>1:321 Pos (1:321 Yes Yes (10) FunctIOning (6211 Segmental duct necrosIs and biliary sludge lill 
;) Pos (1:1281 Pos I> 1:321 Yes Yes (4) FunctIOning (595) Stncturelike changes Iportal edema with 
cholangiolar proliferatIOn and acute 
pericholangitis) and relapSing acute and 
chronic rejection (3551 
4 Pos (>1:321 Pos I > 1:321 No Yes (71 Failed (351 Humoral and acute rejection (35) 
Died (52) Fungal sepsis (521 
;) Pos (> 1:321 Pos 11:321 Yes Yes (121 Functioning (5661 Relapsing acute rejection with stricturelike 
changes (411 and central vl'in sclerosis (561 
6 Pos 11:64) Pos (1:1) No NA Failed (3ll Humoral and acute rejectIOn with duct 
Died (400) strictures (311 
Hepatitis B virus infectIOn with liver fail un' 
i Pos (1:10241 PoSI>I:321 Yes" Yes Failed (3) Humoral rejection (3) 
Functioning (452) 
R Pos (>1:32) Pos (> 1:321 No Yes \7l Failed no) Humoral and acute rejectIOn (10) 
Died (36) Fungal sepsIs 
9 Pos (1:2) Neg No Yes (12) Functioning (659) Nonspecific changes (1741 
10 Pos (> 1:81 Neg Yes Yes (26) Functioning (637) Viral hepatitis (57) 
11 Pos (>1:81 Neg No None Functioning (609) Nonspecific changes on bIOpsy (541 
12 Pos 11:641 Neg Yes Yes (97) Died (1131 Cytomegalovirus hepatitis 1461; respiratory 
arrest (113) 
13 Pos (1:1) Neg No None Functioning (559) Nonspecific changes on biopsy (1531 
14 Pos (NA) Neg Yes Yes (11) Functioning (546) NA 
15 Pos (1:1) Neg No Yes (6) Functioning (533) Stricturelike changes on biopsy (50) 
16 Pos (1:16) Neg Yes Yes (51 Died (44) Bacterial sepsis 
17 Pos 0:512) Neg Yes Yes (U) Functioning (504) NA 
18 Pos (1:2) Neg No Yes (9) Died (45) Stricturelike changes (261; biliary leak and 
reconstruction (39): bacterial sepsis (45) 
19 Pos (NA) Neg Yes Yes (13) Functioning (498) Chronic rejection (440) after withdrawal of 
immunosuppression (Epstein-Barr virus 
infection 1 
20 Pos (1:2561 Neg Yes Yes (14) Functioning (458) Persistent acute rejectIOn 14·22) with infarcts 
and inflammatory arteritis 
21 Pos (1:10241 Neg Yes Yes (13) Functioning (422) Developed septal duct necrosis (2); early chrOniC 
rejection (991 
22 Pos (1:2) Neg Yes None Functioning 14201 NA 
AbbreVIations: NA. not available; Pos, pOSitive; Neg, negative, 
• Patient received PGE, with allograft no.!, but not until day 2 when the liver was already severely damaged and failing. 
rejection. Although there were no graft failures in this 
group, 5 of 13 (38%) patients developed a particularly 
severe fonn of rejection, including 2 patients who had 
relatively high pre transplantation antibody titers (Ta-
ble 3), In the crossmatch negative controls. histologi-
cally documented severe "preservation" injury devel· 
oped in 7 of 10 (70%) patients. whereas 2 patients 
showed mild preservation injury and no biopsy speci-
mens were available in the remaining patient. One of 
the grafts failed from primary dysfunction on day 17. 
Histologically proven rejection was seen in 5 of 8 (637, ) 
patients. 
DISCUSSION 
Characterization of the immunoglobulin class (IgG) 
and titer of lymphocytotoxic anti-donor antibodies 
before transplantation, and monitoring of platelet 
counts, CHlOo activity, CICs and evaluation of a liver 
biopsy specimen after transplantation provided a more 
accurate assessment of the significance of allosensitiza-
tion in clinical liver allografting. Using these monitor-
ing tests, the liver allograft recipients whose cross-
match results were positive were roughly separated 
into two subpopuiations. Preformed IgG lymphocyto-
toxic antibodies disappeared within 1 day after liver 
transplantation in the first group that consisted of a 
majority (14 of 22 [64% I) of the sensitized patients. 
They did not develop thrombocytopenia after trans-
plantation and showed no significant increase of CIC 
or decrease in CHI1"1 activity compared with pretrans-
plantation levels. These results confinn that liver allo-
grafting can reverse alloimmunity as was previously 
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shown in experimental animalss.lo.2G and in combined 
liver-kidney transplantation in humans.27 .2h 
In contrast. donor-reactive IgG antibodies persisted 
for several weeks after transplantation in 8 of22 (36<;{) 
sensitized recipients. After transplantation these pa-
tients also developed refractory thrombocytopenia and 
showed a decrease ofCH lOo activity compared with pre-
transplantation levels and a significant increase of 
CIC. The concomitantly high incidence of allograft fail-
ure in this subgroup because of biopsy results that 
showed humoral and acute (cellular) rejection strongly 
suggests that the alloantibodies contributed to the in-
jury via type II hypersensitivity reactions. which also 
consumed platelets and complement. 
Alternate explanations for the low posttransplanta-
tion complement levels in patients with persistently 
positive crossmatch results are poor liver synthetic 
function or sepsis. We think these explanations are 
unlikely for the following reasons. First. there was a 
strong negative correlation between CHIOU and PT in 
patients whose crossmatch results were negative be-
fore transplantation and in those whose crossmatch 
results became negative after transplantation. In con-
trast. no strong correlation between these two different 
measures of liver synthetic function was seen in the 
patients with persistently positive crossmatch results. 
This suggests that CHIOU activity was tightly linked to 
liver synthetic function in the former two groups but 
not in the latter one. Because the fresh frozen plasma 
and packed red blood cell requirements were the same 
in all three groups, blood component replacement ther-
apy cannot explain the differences in complement lev-
els. Secondly, the CH lOo levels decreased after trans-
plantation only in the patients with persistent 
antibodies. despite comparable pretransplantation lev-
els and no differences in cold ischemic times. The valid-
ity of the controls with negative crossmatch results as 
damaged organs was confirmed functionally (e.g .. 
higher bilirubin values and an increase in PT and in 
AST: Table 2) and histologically and supported by one 
graft failure from primary dysfunction and the develop-
ment of the biliary sludge syndrome in two patients 
included in this groUp.:!9 Lastly. the incidence of sepsis 
was the same in all three groups. 
A more likely explanation for the low CH lOo activity 
is immune consumption caused by activation by anti-
donor antibodies bound in the graft and by CIC. 14•11.30-32 
Complement fixation to antibodv directlv bound to the 
allograft is a well-recognized ~echanisDm of allograft 
damage and complement consumption. However. im-
mune complexes also bind complement that target the 
immune complexes for clearance. In sensitized liver 
allograft recipients. it is likelv that increased CIC 
formed bv anti-donor antibodies' and soluble HLA anti-
gens" 1130·32 shed by the allograft leads to complement 
binding and clearance. If decreased clearance were re-
sponsible for elevated cle. one would expect that the 
same increase of CIe would occur in the controls with 
negative crossmatch results. 
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Consumption within the allograft and increased de-
struction and clearance because of antibody binding 
are also the most likely explanations for the refractory 
thrombocytopenia. 1:1:1 It is well known that platelets 
express HLA class (I) antigens. and specific alloimmu-
nization with these antigens is a major cause of throm-
bocytopenia refractoriness.:!u:; Recently. crossmatch-
ing with platelet targets has been used to avoid 
primary nonfunction in renal transplantation and to 
minimize false-positive reactions of the lymphocyto-
toxic crossmatch.: It; In addition. several previous publi-
cations have shown increased platelet sequestration in 
liver allografts of sensitized recipients.:' :':' 
In our study. the pretransplantation antibody titer 
analysis alone had a good negative-predictive value 
(100%) but a less than optimal positive-predictive value 
(67%) for determining the persistence of anti-donor an-
tibodies and humoral rejection after transplantation. 
This suggests that the anti-donor antibody level is cer-
tainly important. but factors other than the titer can 
influence the subsequent functional consequences and 
determine whether the antibodies persist or disappear 
after transplantation. Similar observations were made 
in experimental animal models.13.:13.37 where liver allo-
graft failure in presensitized rodent recipients was de-
pendent not only on antibody titer:17 but also on anti-
body class (lgGI and specificity.:17 We have previously 
shown the importance of antibody subclass (IgG) in 
clinical liver transplantation. I .:l Moreover, combined 
humoral and acute (cellular) rejection mediated liver 
allograft failure in the sensitized animal model,33.37 and 
this form of rejection is more responsive to increased 
immunosuppression. In other clinical studies of sensi-
tized liver allograft recipients. Karuppan et al 16 and 
Ogura et apl.1 have reported a higher incidence of early 
posttransplantation allograft dysfunction and failure 
in patients with positive crossmatch results. The Mayo 
Clinic group reports no early complications.3!! but they 
do note a higher incidence of "chronic" rejection in sen-
sitized recipientsK~o Lobo et aV I on the other hand, 
found no adverse consequences of sensitization in liver 
allograft recipients. even those with high titer (> 1:64) 
IgG lymphocytotoxic anti-HLA antibodies. It is likely 
that a combination of factors account for the discrepan-
cies. These factors include a more precise characteriza-
tion of the posttransplantation crossmatch state de-
scribed herein. recognition of an antibody mediated 
insult. and local differences in immunosuppressive 
therapy. such as the use of "induction" therapy with 
antileukocyte antibodies and/or high-dose steroids. All 
of the treatments mentioned can lessen the injury asso-
ciated with humoral rejection. 1·:lK4~ 
In our study. only one patient whose crossmatch re-
sults were persistently positive after liver transplanta-
tion and whose graft failed because of humoral reJec-
tion received high-dose steroids and PGE, therapy, but 
she was not treated until day 2 (Table 3). when the 
liver was already severely damaged. Since recognizing 
the increased immunologic risk, 1:1 we routinely include 
4. 
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these agents in all patients with positive crossmatch 
resultsK4~ In addition to inherent immunosuppressive4:1 
and cytoprotectivpll qualities. PGE 1 treatment could 
ameliorate the intense vasoconstriction that occurs 
during antibody-mediated rejection.:u ·, including xeno-
graft models like hamster-to-rat~li and pig-to-dog. 17 
In summary. patients with anti-donor IgG lymphocy-
totoxic antibodies in titers greater than 1:32 are more 
likely to show persistently positive crossmatch results 
after liver transplantation and develop a syndrome 
manifest by low-CH wo activity. increased CIC, and re-
fractory thrombocytopenia. Evaluation of a liver biopsy 
specimen in this group of patients will help identify 
humoral and acute (cellular) rejection as a cause of the 
higher incidence of allograft failure. Identification of 
"at risk" sensitized patients can be used to guide immu-
nosuppressive therapy. However. one must remember 
that these patients are a relatively small percentage of 
the total recipient population (3% in this series). In 
contrast, low-level anti-donor IgG antibodies usually 
do not significantly influence the posttransplantation 
course. even though they may cause a positive result 
in lymphocytotoxic crossmatch tests. 
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